TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20157843

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT) - warfarin, ASA, and clopidogrel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dual therapy (DT) - ASA and clopidogrel
Number of subjects: 20
Study: 19114376

Group type: EXPERIMENTAL
Intervention: Full dose (1 mg/kg) MTW
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Half dose (0.5 mg/kg) MTW
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no MTW)
Number of subjects: 45
Study: 15825548

Group type: EXPERIMENTAL
Intervention: Repinotan 0.5 mg/day
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Repinotan 1.25 mg/day
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Repinotan 2.5 mg/day
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 12861157

Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal irrigation (200 mL of 0.2% chlorhexidine solution every 6 hours during labor)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo (sterile saline solution every 6 hours during labor)
Number of subjects: 1041
Study: 10868308

Group type: EXPERIMENTAL
Intervention: Midazolam syrup (0.25, 0.5, or 1.0 mg/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Midazolam syrup (0.25 to 1.0 mg/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Midazolam syrup (1.0 mg/kg)
Number of subjects: 85
Study: 9207619

Group type: EXPERIMENTAL
Intervention: Dig WD Mild (withdrawn from digoxin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dig WD Moderate (withdrawn from digoxin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dig Cont (continued receiving digoxin)
Number of subjects: 0
Study: 8451491

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 291
Study: 3085906

Group type: EXPERIMENTAL
Intervention: Pirbuterol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29888566

Group type: EXPERIMENTAL
Intervention: Tender-point needling at SP 6, SP 8, and SP 9
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regular acupoint needling at SP 6, SP 8, and SP 9
Number of subjects: 72
Study: 27875025

Group type: EXPERIMENTAL
Intervention: Hyperinsufflation (15 minutes, twice daily)
Number of subjects: 18
Study: 25230593

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (Absorb, Abbott Vascular)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Metallic stent (Xience, Abbott Vascular)
Number of subjects: 501
Study: 22951078

Group type: EXPERIMENTAL
Intervention: Duodenal switch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gastric bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 21998053

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1224
Study: 18155811

Group type: EXPERIMENTAL
Intervention: Combined intradermal (ID) BCG and Hepatitis B (HbsAg 10 microg plus BCG suspension 0.1mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular (IM) Hepatitis B
Number of subjects: 0
Study: 16446025

Group type: EXPERIMENTAL
Intervention: Atosiban intravenously (n=31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nifedipine orally (n=32)
Number of subjects: 63
Study: 14600063

Group type: EXPERIMENTAL
Intervention: 8-session intervention group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 4-session intervention group
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 10817849

Group type: EXPERIMENTAL
Intervention: Nitrate+ (patients using nitrate-containing drugs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitrate- (patients not using nitrate-containing drugs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with CHF (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients with CHF (all groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with CHF (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 40
Study: 8911839

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl anaesthesia + thoracic epidural analgesia
Number of subjects: 54

Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 54
Study: 1687200

Group type: EXPERIMENTAL
Intervention: Ismo-Retard 40 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ismo-Retard 40 mg (15 consecutive once-daily doses)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Imdur 60 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Imdur 60 mg (15 consecutive once-daily doses)
Number of subjects: 44
Study: 6637313

Group type: EXPERIMENTAL
Intervention: Intravenous injection of indomethacin (Confortid) 50 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous injection of 2 mg hydromorphine chloride-atropine (Dilaudid-atropin 1 ml) with a suppository of prochlorperazine (Stemetil) 25 mg
Number of subjects: 50
Study: 30952748

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard Temozolomide-based therapy
Number of subjects: 101
Study: 29068935

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 20
Study: 25915048

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 5881
Study: 25069201

Group type: EXPERIMENTAL
Intervention: Warm acupuncture stimulation of TE 5 combined with routine acupuncture and rehabilitation training (30 min, once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture stimulation of the same acupoints and rehabilitation training (30 min, once daily)
Number of subjects: 60
Study: 21618513

Group type: EXPERIMENTAL
Intervention: Total lignan intake (highest vs. lowest lignan intake quartile)
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Total lignan intake
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Individual or total lignans or proanthocyanidins
Number of subjects: 1859
Study: 19237895

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)-induced pulsatile CPB (group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional linear CPB (group A)
Number of subjects: 80
Study: 17289685

Group type: EXPERIMENTAL
Intervention: Three months of anticoagulation with heparin for five days followed by warfarin (n=369)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Six months of anticoagulation with heparin for five days followed by warfarin (n=380)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Three months of anticoagulation
Number of subjects: 749

Group type: COMPARATOR
Intervention: Six months of anticoagulation
Number of subjects: 749
Study: 15461621

Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with melphalan (MD)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 201
Study: 11413078

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (200 microgram/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral conjugated estrogens (0.625 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous conjugated estrogens
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sublingual estradiol
Number of subjects: 12
Study: 9641731

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH) treatment at a dosage of 0.2 IU/kg/body weight (0.067 mg/kg) subcutaneously daily for 3 years.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (Group 2) with a 1-year observation period followed by a 3-year treatment period.
Number of subjects: 69
Study: 7557720

Group type: EXPERIMENTAL
Intervention: Case management services with legal stipulations as a condition of probation and parole
Number of subjects: 51

Group type: COMPARATOR
Intervention: Case management services without legal stipulations (implied control)
Number of subjects: 51
Study: 2363027

Group type: EXPERIMENTAL
Intervention: High-intensity TENS (3 times the sensory threshold, frequency of 100 Hz)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-intensity TENS (at the sensory threshold, frequency of 100 Hz)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 60
Study: 6781189

Group type: EXPERIMENTAL
Intervention: Heparin administered at an early stage
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heparin administered at a late stage
Number of subjects: 26
Study: 31124839

Group type: EXPERIMENTAL
Intervention: Manual bolus atomization of bupivacaine (1.25 mg/kg diluted in 30 mL normal saline over 30 seconds)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Micropump nebulization of bupivacaine (0.5% undiluted over 10-17.4 minutes)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both delivery methods
Number of subjects: 67
Study: 27348314

Group type: COMPARATOR
Intervention: Limbal-based conventional AGV along-with PK
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pars-plana-modified AGV along-with PK
Number of subjects: 58
Study: 26357864

Group type: EXPERIMENTAL
Intervention: Clonidine (25 μg or 50 μg twice daily for 9 weeks)
Number of subjects: 120
Study: 24327720

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (1,000 IU/day)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU/day)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4,000 IU/day)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 23187322

Group type: EXPERIMENTAL
Intervention: Vibration on contracted quadriceps (VC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vibration on relaxed muscle (VR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham vibration (NV)
Number of subjects: 18
Study: 21146661

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (500 mg aspirin, 600 mg clopidogrel, and tirofiban 25 μg/kg bolus and 0.15 μg/kg per minute maintenance infusion for 18 hours)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (500 mg aspirin and 600 mg clopidogrel)
Number of subjects: 1398
Study: 17549878

Group type: EXPERIMENTAL
Intervention: Phoneme training group (P)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Syllable training group (S)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Onset-rime training group (OR)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Whole-word training group (WW)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 83
Study: 15860853

Group type: EXPERIMENTAL
Intervention: 4‐OHT gel (0.5, 1, or 2 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral tamoxifen (20 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 55
Study: 12475151

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of Rifater (RFT)/Rifinah (RFN)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Separate regimen of four component drugs (INH, RMP, EMB, PZA)
Number of subjects: 105
Study: 10561143

Group type: EXPERIMENTAL
Intervention: Soft Gelatin Capsule (SGC) formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral solution formulation
Number of subjects: 20
Study: 7635420

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 42
Study: 2237981

Group type: EXPERIMENTAL
Intervention: Surgical intervention (carotid endarterectomy)
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Medical intervention
Number of subjects: 3200
Study: 1071698

Group type: EXPERIMENTAL
Intervention: Active treatment (chlorothiazide + alpha-methyldopa and/or a beta-adrenoreceptor antagonist as required)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Overall trial endpoints (death, morbidity from stroke, hypertensive heart and renal disease, and ischaemic heart disease)
Number of subjects: 4000
Study: 30657576

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA)
Number of subjects: 60
Study: 29138555

Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone dipropionate plus formoterol fumarate (BDP-FF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol fumarate (FF)
Number of subjects: 0
Study: 26265639

Group type: EXPERIMENTAL
Intervention: Manual small‐incision cataract surgery (MSICS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Phacoemulsification (PE)
Number of subjects: 52
Study: 21957933

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Guided self-help or e-mail therapy (original trial)
Number of subjects: 88
Study: 21257118

Group type: EXPERIMENTAL
Intervention: 12-session standardized program based on the comprehensive social influence model
Number of subjects: 7079

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7079
Study: 19916211

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16972972

Group type: EXPERIMENTAL
Intervention: Extremely early enteral feeding (breast milk within 24 hours after birth)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (breast milk more than 24 hours after birth)
Number of subjects: 21
Study: 14735178

Group type: EXPERIMENTAL
Intervention: Heliox28 (72% He/28% O(2))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oxygen-enriched air (72% N(2)/28% O(2))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medical air (78.9% N(2)/21.1% O(2))
Number of subjects: 12
Study: 11759742

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9159346

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis (500 mg orally twice a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis
Number of subjects: 90
Study: 7567400

Group type: EXPERIMENTAL
Intervention: Standard instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Evaluative instruction
Number of subjects: 60
Study: 2816477

Group type: EXPERIMENTAL
Intervention: Oral contraceptives for 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives for 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppressed cycles
Number of subjects: 0
Study: 808126

Group type: EXPERIMENTAL
Intervention: Keflex and Keflin (therapeutic doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31449975

Group type: EXPERIMENTAL
Intervention: Inclisiran (a silencing RNA that inhibits PCSK9 synthesis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mipomersen (an antisense oligonucleotide targeting apoB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volanesorsen (APOC3) and ANGPTL3-LRx
Number of subjects: 0
Study: 28851933

Group type: EXPERIMENTAL
Intervention: 0.5 ml/kg/min ELO‐MEL‐isoton (osmolarity = 302 mosmol/l) for 60 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nothing at all (control group)
Number of subjects: 15
Study: 26299520

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-daily
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1498
Study: 23250996

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 22161694

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg daily for 14-17 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19636163

Group type: EXPERIMENTAL
Intervention: Centrum(R)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study: 16784965

Group type: EXPERIMENTAL
Intervention: Chromium-containing milk powder (200 microg/20 g milk powder) twice a day for 16 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15572756

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg) and retinyl palmitate (25,000 IU)
Number of subjects: 18314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18314
Study: 11230889

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy, 100% oxygen for 100 min in a multiplace hyperbaric chamber on 30 occasions over a period of 6 weeks.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group, breathing a gas mixture equivalent to breathing 100% oxygen at surface pressure.
Number of subjects: 34
Study: 9425965

Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6 mg bupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 8 mg bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (spinal lidocaine)
Number of subjects: 90
Study: 8516653

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2850326

Group type: EXPERIMENTAL
Intervention: Alfa LMW1 (8,000 I.U. AXa daily for 6 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31819201

Group type: EXPERIMENTAL
Intervention: Hypoxia training (FiO2 15%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ambient conditions (FiO2 21%)
Number of subjects: 23
Study: 30496229

Group type: EXPERIMENTAL
Intervention: Preschool staff's average activity levels during preschool hours
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Preschool staff's attitudes
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Preschool staff's initiative
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Preschool staff's participation
Number of subjects: 289
Study: 28361576

Group type: EXPERIMENTAL
Intervention: Brisk walking group (BWG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate tempo walking group (MTWG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 26182387

Group type: EXPERIMENTAL
Intervention: Reinforced education by telephone
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Reinforced education by SMS
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Reinforced education groups (telephone and SMS combined)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study: 23764248

Group type: EXPERIMENTAL
Intervention: CT number-controlling system (CTN-CS) for determining contrast amount based on body surface area and peak CT number
Number of subjects: 172

Group type: COMPARATOR
Intervention: Same amount of intravenous contrast in both CCTA examinations
Number of subjects: 172

Group type: COMPARATOR
Intervention: 0.7 mL/mg body weight of contrast medium (350 mgI/mL) for baseline and follow-up CCTAs
Number of subjects: 172
Study: 21992655

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) for 10 weeks, guided by an online therapist, focusing on acceptance of symptoms through exposure and mindfulness training.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting list control group for 10 weeks.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ICBT group at 12-month follow-up.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cost-effectiveness of ICBT compared to waiting list control.
Number of subjects: 61
Study: 17521776

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproic acid (in normal human peripheral blood mononuclear cell cultures)
Number of subjects: 0
Study: 17176013

Group type: EXPERIMENTAL
Intervention: X STOP Interspinous Process Decompression (IPD) System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative therapies
Number of subjects: 0
Study: 14971603

Group type: EXPERIMENTAL
Intervention: Salivary gland scintigraphy scoring system
Number of subjects: 124
Study: 11084187

Group type: EXPERIMENTAL
Intervention: Nicotine patches (15 mg for 8 weeks, then 10 mg for 3 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 250
Study: 8780082

Group type: EXPERIMENTAL
Intervention: 0.3 MU of HLBI for 28 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.0 MU of HLBI for 28 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3.0 MU of HLBI for 28 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: 3.0 MU of HLBI
Number of subjects: 48
Study: 1281015

Group type: EXPERIMENTAL
Intervention: FUT (nafamostat mesilate) 2 mg/kg/hr during CPB and 0.2 mg/kg/hr before and after CPB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FUT (nafamostat mesilate)
Number of subjects: 30
Study: 6146752

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for 14 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31493695

Group type: EXPERIMENTAL
Intervention: Exercise combined with advice
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 240
Study: 28754067

Group type: EXPERIMENTAL
Intervention: Online simulation with role‐playing with emotionally responsive virtual patients
Number of subjects: 227

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 227
Study: 27098971

Group type: EXPERIMENTAL
Intervention: Integrated, multifaceted package of interventions including delayed prescribing, patient decision aids, communication training, commitment to a practice prescribing policy for antibiotics, patient information leaflet, and near patient testing with C-reactive protein.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (standard practice without the intervention).
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with general practitioners and practice staff from the intervention practices.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Economic evaluation of the intervention package.
Number of subjects: 28